The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)
Open accessAbstract
Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist drug action, resulting in increased side effects following drug treatment. A novel therapeutic strategy against cancer cells is the use of anticancer peptides (ACPs). The physicochemical properties, amino acid composition and the addition of chemical groups on the ACP sequence influences their conformation, net charge and orientation of the secondary structure, leading to an effect on targeting specificity and ACP‑cell interaction, as well as peptide penetrating capability, stability and efficacy. ACPs have been developed from both naturally occurring and modified peptides by substituting neutral or anionic amino acid residues with cationic amino acid residues, or by adding a chemical group. The modified peptides lead to an increase in the effectiveness of cancer therapy. Due to this effectiveness, ACPs have recently been improved to form drugs and vaccines, which have sequentially been evaluated in various phases of clinical trials. The development of the ACPs remains focused on generating newly modified ACPs for clinical application in order to decrease the incidence of new cancer cases and decrease the mortality rate. The present review could further facilitate the design of ACPs and increase efficacious ACP therapy in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells
Zwaal, R. F. A., & Schroit, A. J. (1997) · Blood · doi:10.1182/blood.v89.4.1121 · Cited by 1,340
Studies on anticancer activities of antimicrobial peptides
Hoskin, D. W., & Ramamoorthy, A. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.11.008 · Cited by 1,296
Simons, K., & Ikonen, E. (2000) · Science · doi:10.1126/science.290.5497.1721 · Cited by 1,275
Cell-Penetrating Peptides: From Basic Research to Clinics
Guidotti, G., Brambilla, L., & Rossi, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.003 · Cited by 1,147
Cell-Penetrating Peptides: Design, Synthesis, and Applications
Copolovici, D. M., Langel, K., Eriste, E., & Langel, Ü. (2014) · ACS Nano · doi:10.1021/nn4057269 · Cited by 963
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis
Cardone, R. A., Casavola, V., & Reshkin, S. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1713 · Cited by 897
Food-Derived Bioactive Peptides in Human Health: Challenges and Opportunities
Chakrabarti, S., Guha, S., & Majumder, K. (2018) · Nutrients · doi:10.3390/nu10111738 · Cited by 699
Cell-penetrating peptides: breaking through to the other side
Koren, E., & Torchilin, V. P. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.012 · Cited by 670
Thevenet, P., Shen, Y., Maupetit, J., Guyon, F., Derreumaux, P., & Tuffery, P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks419 · Cited by 638
Improved PEP-FOLD Approach for Peptide and Miniprotein Structure Prediction
Shen, Y., Maupetit, J., Derreumaux, P., & Tufféry, P. (2014) · Journal of Chemical Theory and Computation · doi:10.1021/ct500592m · Cited by 636
Rothbard, J. B., Jessop, T. C., Lewis, R. S., Murray, B. A., & Wender, P. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0482536 · Cited by 624
iRSpot-PseDNC: identify recombination spots with pseudo dinucleotide composition
Chen, W., Feng, P.-M., Lin, H., & Chou, K.-C. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1450 · Cited by 611
Modulating the therapeutic response of tumours to dietary serine and glycine starvation
Maddocks, O. D. K., Athineos, D., Cheung, E. C., Lee, P., Zhang, T., van den Broek, N. J. F., Mackay, G. M., Labuschagne, C. F., Gay, D., Kruiswijk, F., et al. (2017) · Nature · doi:10.1038/nature22056 · Cited by 603
Utsugi, T., Schroit, A. J., Connor, J., Bucana, C. D., & Fidler, I. J. (1991) · PubMed · Cited by 594
Cationic amphiphilic peptides with cancer-selective toxicity
Schweizer, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.043 · Cited by 517
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
Milk derived bioactive peptides and their impact on human health – A review
Mohanty, D. P., Mohapatra, S., Misra, S., & Sahu, P. S. (2016) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2015.06.005 · Cited by 494
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
Thundimadathil, J. (2012) · Journal of Amino Acids · doi:10.1155/2012/967347 · Cited by 491
Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
Ran, S., Downes, A., & Thorpe, P. E. (2002) · PubMed · Cited by 471
Taxol (paclitaxel): mechanisms of action.
Horwitz, S. B. (1994) · PubMed · Cited by 434
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
Dathe, M., Schümann, M., Wieprecht, T., Winkler, A., Beyermann, M., Krause, E., Matsuzaki, K., Murase, O., & Bienert, M. (1996) · Biochemistry · doi:10.1021/bi960835f · Cited by 409
CancerPPD: a database of anticancer peptides and proteins
Tyagi, A., Tuknait, A., Anand, P., Gupta, S., Sharma, M., Mathur, D., Joshi, A., Singh, S., Gautam, A., & Raghava, G. P. S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku892 · Cited by 397
Peptides with Dual Antimicrobial and Anticancer Activities
Felício, M. R., Silva, O. N., Gonçalves, S., Santos, N. C., & Franco, O. L. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00005 · Cited by 393
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Oancea, E., Teruel, M. N., Quest, A. F. G., & Meyer, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.3.485 · Cited by 322
In Silico Models for Designing and Discovering Novel Anticancer Peptides
Tyagi, A., Kapoor, P., Kumar, R., Chaudhary, K., Gautam, A., & Raghava, G. P. S. (2013) · Scientific Reports · doi:10.1038/srep02984 · Cited by 320
Peptide-based cancer therapy: Opportunity and challenge
Wu, D., Gao, Y., Qi, Y., Chen, L., Ma, Y., & Li, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.002 · Cited by 306
Bernhardt, S. L., Gjertsen, M. K., Trachsel, S., Møller, M., Eriksen, J. A., Meo, M., Buanes, T., & Gaudernack, G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603437 · Cited by 305
The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
J. Boohaker, R., W. Lee, M., Vishnubhotla, P., M. Perez, J. L., & R. Khaled, A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801661004 · Cited by 302
Hajisharifi, Z., Piryaiee, M., Mohammad Beigi, M., Behbahani, M., & Mohabatkar, H. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2013.08.037 · Cited by 294
Cell-penetrating peptides transport therapeutics into cells
Ramsey, J. D., & Flynn, N. H. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.003 · Cited by 256
A proapoptotic peptide for the treatment of solid tumors.
Mai, J., Mi, Z., Kim, S.-H., Ng, B., & Robbins, P. D. (2001) · PubMed · Cited by 247
Biophysics in cancer: The relevance of drug-membrane interaction studies
Alves, A. C., Ribeiro, D., Nunes, C., & Reis, S. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.06.025 · Cited by 241
Cell-penetrating peptides: strategies for anticancer treatment
Raucher, D., & Ryu, J. S. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.06.005 · Cited by 234
A review of small molecules and drug delivery applications using gold and iron nanoparticles
Jahangirian, H., Kalantari, K., Izadiyan, Z., Rafiee-Moghaddam, R., Shameli, K., & Webster, T. J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s184723 · Cited by 228
Huang, Y.-B., Wang, X.-F., Wang, H.-Y., Liu, Y., & Chen, Y. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0811 · Cited by 224
Peptide-based imaging agents for cancer detection
Sun, X., Li, Y., Liu, T., Li, Z., Zhang, X., & Chen, X. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.007 · Cited by 224
The paradox of Th17 cell functions in tumor immunity
Asadzadeh, Z., Mohammadi, H., Safarzadeh, E., Hemmatzadeh, M., Mahdian-shakib, A., Jadidi-Niaragh, F., Azizi, G., & Baradaran, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.015 · Cited by 219
Proline-rich, amphipathic cell-penetrating peptides
Pujals, S., & Giralt, E. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.012 · Cited by 209
Membrane Permeabilization and Efficient Gene Transfer by a Peptide Containing Several Histidines
Midoux, P., Kichler, A., Boutin, V., Maurizot, J.-C., & Monsigny, M. (1998) · Bioconjugate Chemistry · doi:10.1021/bc9701611 · Cited by 209
Spontaneous Membrane-Translocating Peptides by Orthogonal High-Throughput Screening
Marks, J. R., Placone, J., Hristova, K., & Wimley, W. C. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2017416 · Cited by 203
Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel
Jin, H., Wan, C., Zou, Z., Zhao, G., Zhang, L., Geng, Y., Chen, T., Huang, A., Jiang, F., Feng, J.-P., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08148 · Cited by 201
González-Montoya, M., Hernández-Ledesma, B., Silván, J. M., Mora-Escobedo, R., & Martínez-Villaluenga, C. (2018) · Food Chemistry · doi:10.1016/j.foodchem.2017.09.035 · Cited by 197
On the selectivity and efficacy of defense peptides with respect to cancer cells
Harris, F., Dennison, S. R., Singh, J., & Phoenix, D. A. (2013) · Medicinal Research Reviews · doi:10.1002/med.20252 · Cited by 185
Anticancer β-Hairpin Peptides: Membrane-Induced Folding Triggers Activity
Sinthuvanich, C., Veiga, A. S., Gupta, K., Gaspar, D., Blumenthal, R., & Schneider, J. P. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210569f · Cited by 175
Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites
Marchand, C., Krajewski, K., Lee, H.-F., Antony, S., Johnson, A. A., Amin, R., Roller, P., Kvaratskhelia, M., & Pommier, Y. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl667 · Cited by 171
Barceló-Coblijn, G., Martin, M. L., de Almeida, R. F. M., Noguera-Salvà, M. A., Marcilla-Etxenike, A., Guardiola-Serrano, F., Lüth, A., Kleuser, B., Halver, J. E., & Escribá, P. V. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115484108 · Cited by 170
Increased Exposure of Phosphatidylethanolamine on the Surface of Tumor Vascular Endothelium
Stafford, J. H., & Thorpe, P. E. (2011) · Neoplasia · doi:10.1593/neo.101366 · Cited by 169
Dennison, S., Whittaker, M., Harris, F., & Phoenix, D. (2006) · Current Protein & Peptide Science · doi:10.2174/138920306779025611 · Cited by 168
Membrane fluidity characteristics of human lung cancer
Sok, M., Šentjurc, M., & Schara, M. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00044-0 · Cited by 163
Anti–CTLA-4 therapy requires an Fc domain for efficacy
Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L. R., Garforth, S., Fedorov, E. V., Fedorov, A. A., Bonanno, J. B., Gall, C. M. L., Crowley, S. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801524115 · Cited by 162
Dossa, F., Acuña, S. A., Rickles, A. S., Berho, M. E., Wexner, S. D., Quereshy, F. A., Baxter, N. N., & Chadi, S. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5597 · Cited by 159
Human defensins as cancer biomarkers and antitumour molecules
Droin, N. M., Hendra, J.-B., Ducoroy, P., & Solary, É. (2009) · Journal of Proteomics · doi:10.1016/j.jprot.2009.01.002 · Cited by 156
TumorHoPe: A Database of Tumor Homing Peptides
Kapoor, P., Singh, H., Gautam, A., Chaudhary, K., Kumar, R., & Raghava, G. P. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035187 · Cited by 153
Pattern recognition for predictive, preventive, and personalized medicine in cancer
Cheng, T., & Zhan, X. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0083-9 · Cited by 153
Xu, J., Khan, A. R., Fu, M., Wang, R., Ji, J., & Zhai, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.020 · Cited by 151
Sable, R. V., Parajuli, P., & Jois, S. D. S. (2017) · Marine Drugs · doi:10.3390/md15040124 · Cited by 146
Asymmetric Distribution of Phospholipids in Biomembranes
Yamaji‐Hasegawa, A., & Tsujimoto, M. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1547 · Cited by 144
Extracellular acidity and increased exosome release as key phenotypes of malignant tumors
Logozzi, M., Spugnini, E. P., Mizzoni, D., Raimo, R. D., & Fais, S. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09783-8 · Cited by 140
Roudi, R., Syn, N. L., & Roudbary, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01320 · Cited by 139
Cyclic Cell-Penetrating Peptides as Efficient Intracellular Drug Delivery Tools
Park, S. E., Sajid, M. I., Parang, K., & Tiwari, R. K. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00633 · Cited by 139
Cellular Mucins: Targets for Immunotherapy
Apostolopoulos, V., & McKenzie, I. F. C. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v37.i2-6.110 · Cited by 136
Mandal, P. K., Gao, F., Lü, Z., Ren, Z., Ramesh, R., Birtwistle, J. S., Kaluarachchi, K., Chen, X., Bast, R. C., Liao, W. S. ‐., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000882 · Cited by 136
Therapeutic potential of dairy bioactive peptides: A contemporary perspective
Sultan, S., Huma, N., Butt, M. S., Aleem, M., & Abbas, M. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1136590 · Cited by 131
Peptide-Based Drug Design: Here and Now
Otvos, L. J. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-419-3_1 · Cited by 128
Neuroblastoma tumor cell-binding peptides identified through random peptide phage display
Zhang, J., Spring, H., & Schwab, M. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00575-4 · Cited by 118
Cell-Penetrating Peptides: a Useful Tool for the Delivery of Various Cargoes Into Cells
Böhmová, E., Machová, D., Pechar, M., Pola, R., Venclíková, K., Janoušková, O., & Etrych, T. (2018) · Physiological Research · doi:10.33549/physiolres.933975 · Cited by 115
Unraveling the bioactivity of anticancer peptides as deduced from machine learning
Shoombuatong, W., Schaduangrat, N., & Nantasenamat, C. (2018) · EXCLI journal · doi:10.17179/excli2018-1447 · Cited by 108
Cellular Mucins: Targets for Immunotherapy
Apostolopoulos, V., & McKenzie, I. F. C. (1994) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v14.i3-4.40 · Cited by 108
Designing Anticancer Peptides by Constructive Machine Learning
Grisoni, F., Neuhaus, C. S., Gabernet, G., Müller, A. T., Hiss, J. A., & Schneider, G. (2018) · ChemMedChem · doi:10.1002/cmdc.201800204 · Cited by 107
Asahara, S., Takeda, K., Yamao, K., Maguchi, H., & Yamaue, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-291 · Cited by 102
Perea, S. E., Reyes, O., Baladrón, I., Perera, Y., Fariña, H. G., Gil, J., Rodríguez, A., Bacardí, D., Marcelo, J., Cosme, K., et al. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9814-5 · Cited by 101
Structure-based design for binding peptides in anti-cancer therapy
Wang, S., & Yu, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.024 · Cited by 100
Kang, T., Huang, Y., Zhu, Q., Cheng, H., Pei, Y., Feng, J., Xu, M., Jiang, G., Song, Q., Jiang, T., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.033 · Cited by 99
Lilleby, W. A., Gaudernack, G., Brunsvig, P. F., Vlatkovic, L., Schulz, M., Mills, K., Hole, K. H., & Inderberg, E. M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1994-y · Cited by 97
A new era in anticancer peptide vaccines
Perez, S. A., Hofe, E. V., Kallinteris, N. L., Gritzapis, A. D., Peoples, G. E., Papamichail, M., & Baxevanis, C. N. (2010) · Cancer · doi:10.1002/cncr.24988 · Cited by 95
Therapeutic peptides for cancer therapy. Part I – peptide inhibitors of signal transduction cascades
Bidwell, G. L., & Raucher, D. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903143745 · Cited by 94
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
Herbert, K. J., Ashton, T. M., Prevo, R., Pirovano, G., & Higgins, G. S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1131-7 · Cited by 92
Novel Antimicrobial Peptides with High Anticancer Activity and Selectivity
Chu, H., Yip, B., Chen, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126390 · Cited by 91
Navarro, S., Aleu, J., Jiménez, M. A., Boix, E., Cuchillo, C. M., & Nogués, M. V. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7499-7 · Cited by 88
Liu, X., Cao, R., Wang, S., Jia, J., & Hao, F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02016 · Cited by 87
Yang, Q., Wang, C., Lang, L., Zhou, Y., Wang, H., & Shang, D. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0112-8 · Cited by 84
Structure and function of a custom anticancer peptide, CB1a
Wu, J.-M., Jan, P.-S., Yu, H.-C., Haung, H.-Y., Fang, H., Chang, Y., Cheng, J.-W., & Chen, H. M. (2009) · Peptides · doi:10.1016/j.peptides.2009.02.004 · Cited by 79
Actions and Potential Therapeutic Applications of Growth Hormone–Releasing Hormone Agonists
Schally, A. V., Zhang, X., Cai, R., Hare, J. M., Granata, R., & Bartoli, M. (2019) · Endocrinology · doi:10.1210/en.2019-00111 · Cited by 75
Jobin, M., & Alves, I. D. (2014) · Biochimie · doi:10.1016/j.biochi.2014.07.022 · Cited by 74
Soudy, R., Etayash, H., Bahadorani, K., Lavasanifar, A., & Kaur, K. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00652 · Cited by 74
Leite, M. L., da Cunha, N. B., & Costa, F. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.010 · Cited by 73
Niu, F., Yan, J., Ma, B., Li, S., Shao, Y., He, P., Zhang, W., He, W., Ma, P. X., & Lu, W. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.025 · Cited by 73
Marine Peptides as Anticancer Agents: A Remedy to Mankind by Nature
Negi, B., Kumar, D., & Rawat, D. S. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160724200849 · Cited by 68
Kamei, N., Onuki, Y., Takayama, K., & Takeda‐Morishita, M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23708 · Cited by 66
Resistance to molecularly targeted therapy in non-small-cell lung cancer
Asao, T., Takahashi, F., & Takahashi, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.001 · Cited by 65
Zhou, Y., Liu, X., Xue, J., Liu, L., Tao, L., Li, W., Yang, X., Hou, X., & Fang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02161 · Cited by 65
Kokhaei, P., Palma, M., Hansson, L., Österborg, A., Mellstedt, H., & Choudhury, A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.10.006 · Cited by 64
Yanagisawa, R., Koizumi, T., Koya, T., Sano, K., Koido, S., Nagai, K., Kobayashi, M., Okamoto, M., Sugiyama, H., & Shimodaira, S. (2018) · Anticancer Research · doi:10.21873/anticanres.12464 · Cited by 64
In silico design and optimization of selective membranolytic anticancer peptides
Gabernet, G., Gautschi, D., Müller, A. T., Neuhaus, C. S., Armbrecht, L., Dittrich, P. S., Hiss, J. A., & Schneider, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-47568-9 · Cited by 61
Zhang, W., Li, J., Liu, L., Wang, K., Song, J., Yan, J., Li, Z.-Y., Zhang, B., & Wang, R. (2010) · Peptides · doi:10.1016/j.peptides.2010.06.019 · Cited by 60
Kawaguchi, K., Han, Q., Li, S., Tan, Y., Igarashi, K., Kiyuna, T., Miyake, K., Miyake, M., Chmielowski, B., Nelson, S. D., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1405195 · Cited by 60
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno, S., Kyo, S., Myojo, S., Dohi, S., Ishizaki, J., Miyamoto, K., Morita, S., Sakamoto, J., Enomoto, T., Kimura, T., et al. (2009) · PubMed · Cited by 59
Tsuchiya, N., Hosono, A., Yoshikawa, T., Shoda, K., Nosaka, K., Shimomura, M., Hara, J., Nitani, C., Manabe, A., Yoshihara, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1377872 · Cited by 59
Serrill, J., Wan, X., Hau, A. M., Jang, H. S., Coleman, D. J., Indra, A. K., Alani, A. W. G., McPhail, K. L., & Ishmael, J. E. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0303-x · Cited by 58
Noguchi, M., Matsumoto, K., Uemura, H., Arai, G., Eto, M., Naito, S., Οhyama, C., Nasu, Y., Tanaka, M., Moriya, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1265 · Cited by 57
Dai, Y., Cai, X., Shi, W., Bi, X., Su, X., Pan, M., Li, H., Lin, H., Huang, W., & Qian, H. (2017) · Amino Acids · doi:10.1007/s00726-017-2453-y · Cited by 56
Ishikawa, H., Imano, M., Shiraishi, O., Yasuda, A., Peng, Y., Shinkai, M., Yasuda, T., Imamoto, H., & Shiozaki, H. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0258-6 · Cited by 55
Physiological aspects of membrane lipid fluidity in malignancy.
Deliconstantinos, G. (1987) · PubMed · Cited by 55
Dual-Targeted Molecular Imaging of Cancer
Ehlerding, E. B., Sun, L., Lan, X., Zeng, D., & Cai, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199877 · Cited by 55
Peptide‐Based Proteasome Inhibitors in Anticancer Drug Design
Micale, N., Scarbaci, K., Troiano, V., Ettari, R., Grasso, S., & Zappalà, M. (2014) · Medicinal Research Reviews · doi:10.1002/med.21312 · Cited by 53
Lins, L., Decaffmeyer, M., Thomas, A., & Brasseur, R. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.04.006 · Cited by 53
Obara, W., Eto, M., Mimata, H., Kohri, K., Mitsuhata, N., Miura, I., Shuin, T., Miki, T., Koie, T., Fujimoto, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw675 · Cited by 52
Bhunia, D., Mondal, P., Das, G., Saha, A., Sengupta, P., Jana, J., Mohapatra, S., Chatterjee, S., & Ghosh, S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b10254 · Cited by 52
An Atlas of Anionic Antimicrobial Peptides from Amphibians
Dennison, S. R., Harris, F., Mura, M., & Phoenix, D. A. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203719666180226155035 · Cited by 52
Comparison of Bioactivities of Talactoferrin and Lactoferrins From Human and Bovine Milk
Jiang, R., Du, X., & Lönnerdal, B. L. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000481 · Cited by 51
Combination of aspartic acid and glutamic acid inhibits tumor cell proliferation
Yamaguchi, Y., YAMAMOTO, K., Sato, Y., Inoue, S., Morinaga, T., & Hirano, E. (2016) · Biomedical Research · doi:10.2220/biomedres.37.153 · Cited by 51
Anticancer Activity of Anthopleura anjunae Oligopeptides in Prostate Cancer DU-145 Cells
Wu, Z., Ding, G., Huang, F., Yang, Z., Yu, F., Tang, Y., Jia, Y.-L., Zheng, Y., & Chen, R. (2018) · Marine Drugs · doi:10.3390/md16040125 · Cited by 47
Raucher, D., Moktan, S., Massodi, I., & Bidwell, G. L. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903158909 · Cited by 46
Prateep, A., Sumkhemthong, S., Suksomtip, M., Pithi Chanvorachote, B., & Chaotham, C. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1325913 · Cited by 46
Telomerase activity in human solid tumors. Diagnostic utility and clinical applications.
Vasef, M. A., Ross, J. S., & Cohen, M. B. (1999) · PubMed · Cited by 45
Recent Advances in Peptide-Based Approaches for Cancer Treatment
Conibear, A. C., Schmid, A., Kamalov, M., Becker, C. F. W., & Bello, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867325666171123204851 · Cited by 45
Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach
Kakwere, H., Ingham, E. S., Allen, R. P., Mahakian, L. M., Tam, S. M., Zhang, H., Silvestrini, M. T., Lewis, J. S., & Ferrara, K. W. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00502 · Cited by 44
Dutoit, V., Migliorini, D., Ranzanici, G., Marinari, E., Widmer, V., Lobrinus, J. A., Momjian, S., Costello, J., Walker, P. R., Okada, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1391972 · Cited by 43
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma
Brun, S., Bassissi, F., Serdjebi, C., Novello, M., Tracz, J., Autelitano, F., Guillemot, M., Fabre, P., Courcambeck, J., Ansaldi, C., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00741-3 · Cited by 43
Huang, Y., Li, X., Sha, H., Zhang, L., Bian, X., Han, X., & Liu, B. (2017) · Oncology Reports · doi:10.3892/or.2017.5440 · Cited by 42
Buckton, L. K., & McAlpine, S. R. (2018) · Organic Letters · doi:10.1021/acs.orglett.7b03363 · Cited by 42
Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Engel, J. B., Tinneberg, H., Rick, F. G., et al. (2016) · Current Drug Targets · doi:10.2174/138945011705160303154717 · Cited by 41
Kozłowska, K., Nowak, J., Kwiatkowski, B., & Cichorek, M. (1999) · Experimental and Toxicologic Pathology · doi:10.1016/s0940-2993(99)80074-8 · Cited by 40
Antifungal and antitumor models of bioactive protective peptides
Rodrigues, E. G., Dobroff, A. S., Taborda, C. P., & Travassos, L. R. (2009) · Anais da Academia Brasileira de Ciências · doi:10.1590/s0001-37652009000300015 · Cited by 40
Søgaard, C. K., Moestue, S. A., Rye, M. B., Kim, J., Nepal, A., Liabakk, N., Bachke, S., Bathen, T. F., Otterlei, M., & Hill, D. K. (2018) · Oncotarget · doi:10.18632/oncotarget.24357 · Cited by 40
Garofalo, M., Grazioso, G., Cavalli, A., & Sgrignani, J. (2020) · Molecules · doi:10.3390/molecules25071756 · Cited by 40
Brown, T. A., Byrd, K. A., Vreeland, T. J., Clifton, G. T., Jackson, D. O., Hale, D. F., Herbert, G. S., Myers, J. W., Greene, J. M., Berry, J. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2378 · Cited by 39
Peptide‐based targeted therapeutics and apoptosis imaging probes for cancer therapy
Vadevoo, S. M. P., Gurung, S., Khan, F., Haque, M. E., Gunassekaran, G. R., Chi, L., Permpoon, U., & Lee, B. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01125-0 · Cited by 38
Li, Q.-X., Yu, D., Liu, G., Ke, N., McKelvy, J. F., & Wong‐Staal, F. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.48 · Cited by 38
Wang, C., Chen, Y.-W., Zhang, L., Gong, X.-G., Zhou, Y., & Shang, D. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1113539 · Cited by 38
Antonilli, M., Rahimi, H., Visconti, V. V., Napoletano, C., Ruscito, I., Zizzari, I. G., Caponnetto, S., Barchiesi, G., Iadarola, R., Pierelli, L., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3386 · Cited by 38
Margolin, K. A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1495 · Cited by 37
Lyu, L., Huang, L., Huang, T., Xiang, W., Yuan, J., & Zhang, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s161821 · Cited by 37
Perry, S. R., Hill, T. A., de Araujo, A. D., Hoang, H. N., & Fairlie, D. P. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02952g · Cited by 36
KISS1 in breast cancer progression and autophagy
Ulasov, I. V., Borovjagin, A. V., Timashev, P. S., Cristofanili, M., & Welch, D. R. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09814-4 · Cited by 34
Wang, X., Chen, X., Yang, X., Gao, W., He, B., Dai, W., Zhang, H., Wang, X., Wang, J., Zhang, X., et al. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.360 · Cited by 33
Di, J.-X., & Zhang, H. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000783 · Cited by 33
Increased cellular uptake of peptide-modified PEGylated gold nanoparticles
He, B., Yang, D., Qin, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.026 · Cited by 32
Rodríguez‐Ulloa, A., Ramos, Y., Gil, J., Perera, Y., Castellanos, L., Garcı́a, Y., Betancourt, L. H., Besada, V., González, L. J., Fernández-de-Cossío, J., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr100728v · Cited by 31
Kim‐Schulze, S., Taback, B., & Kaufman, H. L. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.011 · Cited by 30
Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy
Meng, F., Han, N., & Yeo, Y. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1218464 · Cited by 29
Leptin OB3 peptide suppresses leptin-induced signaling and progression in ovarian cancer cells
Chin, Y., Wang, L.-M., Hsieh, M.-T., Shih, Y.-J., Nana, A. W., Changou, C. A., Yang, Y.-C. S. H., Chiu, H., Fu, E., Davis, P. J., et al. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0356-6 · Cited by 29
Foldamers as Anticancer Therapeutics: Targeting Protein–Protein Interactions and the Cell Membrane
Fahs, S., Patil‐Sen, Y., & Snape, T. J. (2015) · ChemBioChem · doi:10.1002/cbic.201500188 · Cited by 28
A review of the design and modification of lactoferricins and their derivatives
Hao, Y., Yang, N., Teng, D., Wang, X., Mao, R., & Wang, J. (2018) · BioMetals · doi:10.1007/s10534-018-0086-6 · Cited by 28
A novel peptide targeting gastrin releasing peptide receptor for pancreatic neoplasm detection
Tu, Y., Ji, T., Wang, F., Liu, P., Han, Z., Li, Z., Ma, Y., & Gu, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm00162g · Cited by 27
Zachos, I., Konstantinopoulos, P. A., Tzortzis, V., Gravas, S., Karatzas, A. D., Karamouzis, M. V., Melekos, M. D., & Papavassiliou, A. G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.496450 · Cited by 26
Rausch, S., Gouttefangeas, C., Hennenlotter, J., Laske, K., Walter, K., Feyerabend, S., Chandran, P. A., Kruck, S., Singh‐Jasuja, H., Frick, A., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.09.009 · Cited by 26
A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317–326 Peptide
Barras, D., Chevalier, N., Zoete, V., Dempsey, R., Lapouge, K., Olayioye, M. A., Michielin, O. A., & Widmann, C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.576272 · Cited by 24
Zhang, B., Shi, W., Li, J., Liao, C., Yang, L.-M. C., Huang, W., & Qian, H. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13023 · Cited by 24
Wang, Q., Li, S.-B., Zhao, Y.-Y., Dai, D.-N., Du, H., Lin, Y.-Z., Ye, J.-C., Zhao, J., Xiao, W., Yan, M., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.019 · Cited by 24
Past, Present, and Future of Targeting Ras for Cancer Therapies
Tan, Z., & Zhang, S. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001154111 · Cited by 23
Singh, M., Kumar, V., Sikka, K., Thakur, R. K., Harioudh, M. K., Mishra, D. P., Ghosh, J. K., & Siddiqi, M. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00348 · Cited by 23
Jimenez, J. J., DelCanto, G. M., Popovics, P., Perez, A., Granda, A. V., Vidaurre, I., Cai, R., Rick, F. G., Swords, R. T., & Schally, A. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15207 · Cited by 21
Fine-tuning the physicochemical properties of peptide-based blood–brain barrier shuttles
Ghasemy, S., García‐Pindado, J., Aboutalebi, F., Dormiani, K., Teixidò, M., & Malakoutikhah, M. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.009 · Cited by 20
Muñoz‐Moreno, L., Bajo, A. M., Prieto, J. C., & Carmena, M. J. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.011 · Cited by 19
Wang, X., Zhang, L., Ding, N., Yang, X., Zhang, J., Jiang, H., Li, Z., & Sun, L. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.033 · Cited by 18
Mikecin, A., Walker, L. R., Kuna, M., & Raucher, D. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000036 · Cited by 18
Hirabayashi, K., Yanagisawa, R., Saito, S., Higuchi, Y., Koya, T., Sano, K., Koido, S., Okamoto, M., Sugiyama, H., Nakazawa, Y., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12465 · Cited by 16
Zhang, H., Han, D., Lv, T., Liu, K., Yang, Y., Xu, X., & Chen, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s207224 · Cited by 16
ChBac3.4: A Novel Proline-Rich Antimicrobial Peptide from Goat Leukocytes
Валерьевна, Ш. О., Orlov, D. S., Stegemann, C., Czihal, P., Hoffmann, R., Brogden, K. A., Kolodkin, N. I., Sakuta, G. A., Tossi, A., Sahl, H., et al. (2009) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-009-9170-7 · Cited by 16
Dhar, A., Mallick, S., Ghosh, P., Maiti, A., Ahmed, I., Bhattacharya, S., Mandal, T., Manna, A. K., Roy, K., Singh, S., et al. (2014) · Biopolymers · doi:10.1002/bip.22505 · Cited by 14
The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2
Lamidi, O. F., Sani, M., Lazzari, P., Zanda, M., & Fleming, I. N. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1921-6 · Cited by 13
Aspeslagh, S., Awada, A. H., Matos-Pita, A. S., Aftimos, P. G., Bahleda, R., Varga, A., & Soria, J. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000409 · Cited by 13
Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures
Korani, M., Korani, S., Zendedel, E., Nikpoor, A. R., Jaafari, M. R., Orafai, H. M., Johnston, T. P., & Sahebkar, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191106150018 · Cited by 11
Zebrafish as a model to evaluate peptide-related cancer therapies
Shull, A. Y., Hu, C.-A. A., & Teng, Y. (2017) · Amino Acids · doi:10.1007/s00726-017-2388-3 · Cited by 9
Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno, S., Takano, F., Ohta, Y., Kyo, S., Myojo, S., Dohi, S., Sugiyama, H., Ohta, T., & Inoue, M. (2011) · PubMed · Cited by 8
Adlakha, S., Sharma, A., Vaghasiya, K., Ray, E., & Verma, R. K. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203721666191231110453 · Cited by 7
Cited by
Bridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
AAontology: An Ontology of Amino Acid Scales for Interpretable Machine Learning
Breimann, S., Kamp, F., Steiner, H., & Frishman, D. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168717 · Cited by 15
Furukawa, N., Yang, W., Chao, A. R., Patil, A., Mirando, A. C., Pandey, N. B., & Popel, A. S. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01932-5 · Cited by 10
Metadata
- Authors
- Chiangjong, W., Chutipongtanate, S., & Hongeng, S.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2020-07-10
- Volume
- 57
- Issue
- 3
- Pages
- 678-696
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W3041538267
- Cited by
- 388
- References
- 174
- FWCI
- 24.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.